NCT06287229 · Recruiting
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

Start your clinical trial request

Sign in to choose who this request is for, add supporting documents, and send it to our clinical team.

Your request is reviewed and a WeTrials Clinical Navigator will contact you in 1–2 business days. Your profiles and documents stay private to you.

New to WeTrials? Continuing creates your account.